| Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT) (NCT05445752) | Hospital Universitario Virgen Macarena | 2022-07-01 |
| CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma (NCT05289193) | Memorial Sloan Kettering Cancer Center | 2022-03-11 |
| Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (NCT05402059) | MelanomaPRO, Russia | 2022-03-02 |
| MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] (NCT06299878) | Russian Academy of Medical Sciences | 2022-01-01 |
| (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma (NCT05767879) | Leiden University Medical Center | 2022-01-01 |
| pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE (NCT05171374) | MelanomaPRO, Russia | 2021-09-30 |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma (NCT04741997) | H. Lee Moffitt Cancer Center and Research Institute | 2021-05-24 |
| A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment (NCT04526899) | BioNTech SE | 2021-05-19 |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma (NCT04598009) | University of California, San Francisco | 2021-03-03 |
| Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors (NCT04675346) | Oxford University Hospitals NHS Trust | 2020-11-18 |
| A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (NCT04207086) | Melanoma Institute Australia | 2020-11-11 |
| Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma (NCT04513028) | Kelly McMasters | 2020-11-03 |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients (NCT04562129) | H. Lee Moffitt Cancer Center and Research Institute | 2020-09-24 |
| Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease (NCT04330430) | The Netherlands Cancer Institute | 2020-09-08 |
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis (NCT04305145) | Massachusetts General Hospital | 2020-08-31 |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (NCT04410445) | Nektar Therapeutics | 2020-07-27 |
| Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 (NCT04455503) | Evaxion Biotech A/S | 2020-07-13 |
| Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma (NCT04139902) | Diwakar Davar | 2020-06-12 |
| Appropriate Dosing to Optimise Personalised Cancer Treatments (NCT04154163) | University of Dundee | 2020-01-10 |
| Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab (NCT04013854) | Abramson Cancer Center at Penn Medicine | 2020-01-01 |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (NCT04045691) | Pierre Fabre Pharma GmbH | 2019-10-17 |
| A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma (NCT04007588) | Dana-Farber Cancer Institute | 2019-09-06 |
| SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) (NCT04079166) | Scancell Ltd | 2019-08-19 |
| SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab (NCT03161431) | Syntrix Biosystems, Inc. | 2019-06-12 |
| Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (NCT03620019) | UNC Lineberger Comprehensive Cancer Center | 2018-09-10 |
| Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain (NCT03605771) | Grupo Español Multidisciplinar de Melanoma | 2018-08-07 |
| Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (NCT03161756) | Melanoma and Skin Cancer Trials Limited | 2017-12-07 |
| A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma (NCT03153085) | Takara Bio Inc. | 2017-05-25 |
| Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma (NCT03190824) | Syneos Health | 2016-12-22 |
| Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin (NCT07671495) | MIPO Clinic | 2014-01-01 |